A new study uncovers novel copy number signatures in ovarian cancer genomes. This work sheds light on mutational processes driving ovarian cancer, reveals the distribution of copy number features across the patient population and identifies new genomic properties related to treatment response.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability
Chromosome Research Open Access 17 August 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cancer Genome Atlas Research Network. Nature 474, 609–615 (2011).
McIntyre, G. et al. Nat. Genet. https://doi.org/10.1038/s41588-018-0179-8 (2018).
Patch, A.-M. et al. Nature 521, 489–494 (2015).
McPherson, A. et al. Nat. Genet. 48, 758–767 (2016).
Wang, Y. K. et al. Nat. Genet. 49, 856–865 (2017).
Davies, H. et al. Nat. Med. 23, 517–525 (2017).
Alexandrov, L. B. et al. Nature 500, 415–421 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing Interests
S.P.S. is a principal shareholder of Contextual Genomics, Inc.
Rights and permissions
About this article
Cite this article
Shah, S.P. Copy number signatures in ovarian cancer. Nat Genet 50, 1208–1209 (2018). https://doi.org/10.1038/s41588-018-0212-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-018-0212-y
This article is cited by
-
Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability
Chromosome Research (2023)
-
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Nature Reviews Cancer (2022)